Clinical trial

Melatonin Versus Placebo for Benzodiazepine Discontinuation in Patients With Schizophrenia

NCT01431092

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Placebo Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Melatonin Normalized identity: melatoninView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Melatonin Versus Placebo for Benzodiazepine Discontinuation in Patients With Schizophrenia

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE4

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2011-10-01

PhasePHASE4

Conditions

Schizophreniaverified · MONDO: schizophrenia

Schizoaffective Disorderverified · MONDO: schizoaffective disorder

Bipolar Affective Disorderunresolved

Interventions

PlaceboDRUG

MelatoninDRUG · verified · RxNorm: melatonin

Sponsors & collaborators

Lone Baandruplead sponsor

Glostrup University Hospital, Copenhagencollaborator

Copenhagen Trial Unit, Center for Clinical Intervention Researchcollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01431092 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.